HC Wainwright Reiterates Buy Rating for Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $10.00 price objective on the stock.

Separately, Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Friday, March 22nd.

Compass Therapeutics Price Performance

CMPX stock opened at $1.53 on Tuesday. The company’s 50 day simple moving average is $1.85 and its 200-day simple moving average is $1.73. The firm has a market capitalization of $210.51 million, a PE ratio of -4.50 and a beta of 0.78. Compass Therapeutics has a 12 month low of $1.15 and a 12 month high of $3.62.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Thursday, March 21st. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). As a group, sell-side analysts anticipate that Compass Therapeutics will post -0.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its stake in shares of Compass Therapeutics by 577.2% in the first quarter. Tower Research Capital LLC TRC now owns 7,855 shares of the company’s stock worth $26,000 after acquiring an additional 6,695 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Compass Therapeutics in the second quarter worth $35,000. Alliancebernstein L.P. acquired a new position in Compass Therapeutics during the second quarter worth $36,000. UBS Group AG increased its position in Compass Therapeutics by 63.5% during the fourth quarter. UBS Group AG now owns 11,819 shares of the company’s stock worth $59,000 after buying an additional 4,591 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new position in Compass Therapeutics during the second quarter worth $38,000. 68.43% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.